Lorraine Pelosof

2.8k citations

35 papers · 1.8k indexed · h-index 16

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Cancer Research top 10%
- Cancer Genomics and Diagnostics

Papers in

Oncology 18
- Cancer Immunotherapy and Biomarkers 8
- Colorectal Cancer Treatments and Studies 6
- Pancreatic and Hepatic Oncology Research 3
- HER2/EGFR in Cancer Research 3
Hepatology 4
- Hepatocellular Carcinoma Treatment and Prognosis 4

Co-authors: David E. Gerber Daniel E. Goldberg Wandy L. Beatty Michael Klemba Ritu BanerjeeJun LiuAmy S. Rosenberg Mark Avigan
Journals: Journal of Clinical Oncology (7 papers)The Oncologist (4 papers)Cancer Research (2 papers)Liver International (1 paper)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations: United States United Kingdom Canada

In The Last Decade

Lorraine Pelosof

32 papers receiving 1.8k citations

Peers

Countries citing papers authored by Lorraine Pelosof

Since Specialization

Citations

This map shows the geographic impact of Lorraine Pelosof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorraine Pelosof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorraine Pelosof more than expected).

Fields of papers citing papers by Lorraine Pelosof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorraine Pelosof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorraine Pelosof. The network helps show where Lorraine Pelosof may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lorraine Pelosof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lorraine Pelosof Line = papers co-authored together Lorraine Pelosof links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following prior therapies for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs). Journal of Clinical Oncology ·Lian Odeh, Kurnia Indah Fatmawati, J. Theodore Peña, Rubén Zamudio, Z. Ye, Abida Bashir, Shifa Marlieva, Risa Liang Wong, C. Jaegermann, Fu Yuanhuan, Maria Marta Rios, 速男井上, S.E. Davies, A. D. Sakharov, Lorraine Pelosof, Mozhdeh Khosravian-Hemamai, Jinmeng Chen	2026	0
2	ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs). Journal of Clinical Oncology ·Rohit Jain, Rubén Zamudio, Bishoy M. Faltas, Scott T. Tagawa, Di Jiang, 速男井上, Syeda Mahrukh Hussnain Naqvi, Youngchul Kim, Lorraine Pelosof, Yuanquan Yang, Laura Graham, Marcia Morales, Timothy W. Synold, Zhao Jin, Jingsong Zhang, 泰洋本多, Guru Sonpavde	2025	0
3	A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors. Journal of Clinical Oncology ·Aman Chauhan, Charles A. Kunos, Susanne M. Arnold, Heidi L. Weiss, S. Percy Ivy, Steven D. Gore, Larry Rubinstein, Lorraine Pelosof, Jan H. Beumer, Jill Kolesar, William E. Carson, Elise C. Kohn, Lowell Anthony	2024	0
4	Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma Blood ·Jennifer E. Amengual, Aung M. Tun, Robin H. Ryder, S. Padmanathan, Victor Yazbeck, Tsutomu Kitajima, Seda S. Tolu, Barbara Pro, Diane E. Durecki, Jan H. Beumer, Neil L. Kelleher, Qin Hongyu, Осипов Алексей Сергеевич, J D Kumkar, 宝碧徐, Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz	2024	2
5	Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS). Journal of Clinical Oncology ·C. Broussolle, Matthew Ingham, Li Chen, Biswajit Das, Shing M. Lee, 池永澤, Mihaela Druta, Anthony P. Conley, Mary Louise Keohan, Mark Agulnik, Melissa Burgess, A. Chalmers, Gina Z. D’Amato, Benjamin Powers, Mahesh Seetharam, Brittany L. Siontis, Lorraine Pelosof, Brian Andrew Van Tine, Gary K. Schwartz, Franciszek Kalata	2024	3
6	Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma JHEP Reports ·David J. Pinato, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Matthias Pinter, Guo Wei, Julie A. Schneider, Donna R. Rivera, Richard Pazdur, Marc R. Theoret, Sandra J. Casak, Steven J. Lemery, Lola A. Fashoyin‐Aje, Alessio Cortellini, Lorraine Pelosof	2023	33
7	Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1 Pharmaceutics ·Nishant Mohan, Shang Yuan-ming, Yi Shen, Cruz Apestegui Cardenal, Yukinori Endo, Milos Dokmanovic, Deborah H. Schmiel, Jiwen Zheng, David S. Rotstein, Lorraine Pelosof, Wen Jin Wu	2022	2
8	FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib The Oncologist ·May Tun Saung, Lorraine Pelosof, Sandra J. Casak, Martha Donoghue, Steven J. Lemery, Mengdie Yuan, Lisa Rodríguez, Katarzyna Gajdel, Meredith K. Chuk, A. Lawalree, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola A. Fashoyin‐Aje	2021	77
9	Deciphering the Dynamic Complexities of the Liver Microenvironment — Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI) The AAPS Journal ·Tao Wang, Matthew M. Yeh, Mark Avigan, Lorraine Pelosof, Gerald M. Feldman	2021	1
10	Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy The Oncologist ·Lorraine Pelosof, May Tun Saung, Martha Donoghue, Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Xiling Jiang, Jiang Liu, Hong Zhao, Larry Donohoo, Kirsten B. Goldberg, Marc R. Theoret, Steven J. Lemery, Richard Pazdur, Lola A. Fashoyin‐Aje	2020	9
11	NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes Frontiers in Immunology ·Lai Xu, Lorraine Pelosof, Rong Wang, B M Shchepotin, Wells W. Wu, Je‐Nie Phue, Chun‐Ting Lee, Rong‐Fong Shen, Hartmut Juhl, Leihong Wu, Florian Andreas Beerlage, Neil Watkiss, Amy S. Rosenberg	2020	12
12	Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues BMC Medical Genetics ·Lai Xu, Helen Luo, Rong Wang, Wells W. Wu, Je‐Nie Phue, Rong‐Fong Shen, Hartmut Juhl, Leihong Wu, Frédéric Mora, Vahan Simonyan, Lorraine Pelosof, Amy S. Rosenberg	2019	17
13	Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib The Oncologist ·Lorraine Pelosof, Steven J. Lemery, Sandra J. Casak, Xiaoping Jiang, Lisa Rodríguez, Gabidullina R.I. Gabidullina, Youwei Bi, Jiang Liu, Jeanne Fourie Zirkelbach, 直人菊地, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur	2018	15
14	Proportion of Never-Smoker Non–Small Cell Lung Cancer Patients at Three Diverse Institutions JNCI Journal of the National Cancer Institute ·Lorraine Pelosof, Chul Ahn, Ang Gao, Leora Horn, 検裕中井, В. С. Балмашев, Chris Grieves, John D. Minna, Adi F. Gazdar, Steven Rutherford	2016	108
15	GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer Epigenetics ·Lorraine Pelosof, Chen-Guang Yu, Todd D. Armstrong, Pingping Zhang, Ludmila Danilova, 雅俊中源, Manuel Hidalgo, Nilofer S. Azad, James G. Herman	2016	47
16	27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination European Journal of Cancer ·義博高木, Mark Voskoboynik, Jon Infante, Andrew Brenner, Manish R. Patel, Erkut Borazanci, Gerald S. Falchook, L. Rhoda Molife, Shubham Pant, Emma Dean, Lorraine Pelosof, Suzanne F. Jones, Chris Rubino, William McCulloch, Anokhin A.O., George Kemble, Marie O’Farrell, Florian Baumgartner	2015	5
17	Abstract 1155: Promoter CpG island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in colorectal cancer. Cancer Research ·Linda J.W. Bosch, Geert Trooskens, Pétur Snæbjörnsson, Josien Haan, Lorraine Pelosof, Miriam Koopman, Jolien Tol, Joost Louwagie, Luc Dehaspe, Bauke Ylstra, Henk M.W. Verheul, Manon van Engeland, Irıs D. Nagtegaal, James G. Herman, Cornelis J.A. Punt, Wim Van Criekinge, Beatriz Carvalho, Gerrit A. Meijer	2013	1
18	Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment Mayo Clinic Proceedings ·Lorraine Pelosof, David E. Gerber	2010	435
19	Retrograde jejunogastric intussusception caused by a migrated gastrostomy tube Endoscopy ·Lorraine Pelosof, Daniel A. Ringold, Reineke Bochum-Bad Lippspringe, Sanjeev Bhalla, Yoshinobu Shiba, Gary R. Zuckerman	2007	12
20	Co-ordinate but disproportionate activation of apoptotic, regenerative and inflammatory pathways characterizes the liver response to acute amebic infection Cellular Microbiology ·Lorraine Pelosof, Paul H. Davis, Zhi Zhang, Xiaochun Zhang, Samuel L. Stanley	2005	13

About Lorraine Pelosof

Lorraine Pelosof is a scholar working on Oncology, Hepatology, Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 35 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Genomics and Diagnostics (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Oncology (694 citations), Cancer Research (224 citations), Hepatology (101 citations), Neurology (193 citations) and Public Health, Environmental and Occupational Health (314 citations). Lorraine Pelosof has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include David E. Gerber, Daniel E. Goldberg, Wandy L. Beatty, Michael Klemba, Ritu Banerjee, Jun Liu, Amy S. Rosenberg, Mark Avigan, Daniel L. Suzman and Richard Pazdur. Their work appears in journals such as Journal of Clinical Oncology, The Oncologist, Cancer Research, Liver International and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact